LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

Niels Reinmuth, Filippo de Marinis, Natasha B. Leighl et al.|Immuno-Oncology Technology|2023

Cited by 2